Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (3 active)
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Type
(
1 selected
)
Type
Guidance (39)
Guidance programme
(
1 selected
)
Guidance programme
NICE guidelines (1)
Technology appraisal guidance (39)
Apply filters
Showing 1 to 10 of 39
Sort by
Title
Date
Apply sorting
lung cancer
Remove lung cancer filter
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Alectinib for adjuvant treatment of ALK-positive non-small-cell
lung cancer
[ID6368]
Technology appraisal guidance
11 December 2024
Atezolizumab for untreated advanced or recurrent non-small cell
lung cancer
when platinum-doublet chemotherapy is unsuitable ID6218
Technology appraisal guidance
TBC
Atezolizumab with cabozantinib for treating metastatic non-small-cell
lung cancer
after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]
Technology appraisal guidance
TBC
Aumolertinib for untreated EGFR mutation-positive non-small-cell
lung cancer
[ID4000]
Technology appraisal guidance
TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell
lung cancer
[ID1261]
Technology appraisal guidance
TBC
Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell
lung cancer
[ID5114]
Technology appraisal guidance
TBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell
lung cancer
[ID3949]
Technology appraisal guidance
TBC
Cimavax for treating wild-type EGFR-positive non-small-cell
lung cancer
[1259]
Technology appraisal guidance
TBC
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell
lung cancer
after anti-PD-L1 treatment and chemotherapy [ID6398]
Technology appraisal guidance
TBC
Crizotinib for treating ROS1-positive advanced non-small-cell
lung cancer
(MA review of TA529) [ID6289]
Technology appraisal guidance
16 October 2024
Current page
1
2
3
4
Page
1
of
4
Next page
Results per page
10
25
50
All
Back to top